Skip to main content
    E

    Eton Pharmaceuticals Inc (ETON)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $56.46
    +9.31 (+19.75%)

    Market Cap: $1.35B

    Last updated: Nov 06, 2026 at 4:24 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(16/30)
    Avg Surprise
    -35.51%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.70
    Range$0.58 - $0.82
    2 analysts
    Revenue Consensus
    $58M
    Range$56M - $61M
    4 analysts
    Last 12 of 34 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.70$0.58 - $0.82--2--
    Sep 26
    Reported Nov 5
    		$1.06$0.34$0.32 - $0.42+211.76%Beat2
    1
    0
    30d
    		+2550.0%
    Jun 26
    Reported Aug 13
    		$0.35$0.11$0.11 - $0.11+218.18%Beat2
    0
    1
    30d
    		+450.0%
    Mar 26
    Reported May 14
    		$0.14$0.14$0.14 - $0.14+0.00%Beat1
    0
    1
    30d
    		+333.3%
    Dec 25
    Reported Mar 19
    		$0.19$0.18$0.18 - $0.18+5.56%Beat1
    1
    0
    30d
    		+1050.0%
    Sep 25
    Reported Nov 6
    		$0.04N/A--75.00%Miss1
    1
    0
    30d
    		+100.0%
    Jun 25
    Reported Aug 7
    		$-0.10$-0.01$-0.01 - $0.08-900.00%Miss3
    1
    0
    30d
    		+16.7%
    Mar 25
    Reported May 13
    		$-0.06$0.05$-0.01 - $0.13-220.00%Miss3
    1
    0
    30d
    		-100.0%
    Dec 24
    Reported Mar 18
    		$-0.02$-0.00$-0.01 - $-0.00-506.06%Miss2
    No revisions (30d)
    		+77.8%
    Sep 24
    Reported Nov 12
    		$0.02$-0.01$-0.01 - $-0.01+300.00%Beat2
    No revisions (30d)
    		+200.0%
    Jun 24
    Reported Aug 8
    		$-0.12$-0.07$-0.07 - $-0.07-71.43%Miss1
    No revisions (30d)
    		-166.7%
    Mar 24
    Reported May 9
    		$-0.03N/A-+57.14%Beat1
    No revisions (30d)
    		+70.0%
    Dec 23
    Reported Mar 14
    		$-0.09$-0.04$-0.04 - $-0.04-125.00%Miss1
    No revisions (30d)
    		-325.0%

    Key Metrics

    Valuation
    P/E Ratio32.45EV/EBITDA34.23x
    Price/FCF42.35xFCF Yield2.36%
    Profitability
    Profit Margin12.00%Operating Margin35.80%
    ROE36.00%ROIC36.99%
    Financial Health
    Debt/Equity0.27xInterest CoverageN/A
    Current Ratio1.79xQuick Ratio1.58x
    Trading Statistics
    Beta0.83Avg Volume460.44K
    52-Week High$66.3752-Week Low$14.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$51.51
    SMA 20$51.34
    SMA 50$54.80
    SMA 200$36.61
    EMA 10$51.62
    EMA 20$51.97
    EMA 50$52.34
    EMA 200$40.46

    MACD

    Line: -0.67Signal: -1.04Hist: 0.37

    ADX

    ADX: 24.1+DI: 22.7-DI: 20.6

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down96.0
    PSAR$47.03

    Bollinger Bands

    Upper Band$55.66
    Lower Band$47.03
    %B Position1682%(Upper)
    Band Width1.09

    RSI (14-Day)

    Neutral
    59.0

    Momentum Oscillators

    Stoch %K41.8
    Stoch %D35.6
    Williams %R-18.4
    ROC (10d)12.9%
    Momentum6.46
    CCI (20d)163.2
    MFI (14d)65.4

    Volatility Measures

    ATR (14d)$3.43(6.1%)
    StdDev (20d)2.16
    Hist Vol82.3%(High)

    Volume Flow

    VWAP$55.62
    OBV19.5M
    AD Line2.0M
    CMF (20d)-0.183

    Volume Metrics

    Avg Vol (20d)460.8K
    Vol Ratio2.8x(High)
    VWMA (20d)$51.75

    Pivot Points

    R3$55.34
    R2$53.66
    R1$50.40
    Pivot Point$48.72
    S1$45.46
    S2$43.78
    S3$40.52

    Advanced Oscillators

    TSI-8.21
    Ultimate Osc49.8
    KST-70.93

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$57.92M$37.59M$24.27M$21.28M$22.46M$18.93M$17.28M$11.65M$10.32M$9.07M$7.97M$7.31M
    Cost of Revenue$13.62M$12.18M$9.53M$8.18M$14.60M$7.00M$7.42M$5.17M$4.02M$3.45M$2.96M$3.68M
    Gross Profit$44.30M$25.41M$14.73M$13.10M$7.86M$11.92M$9.86M$6.48M$6.30M$5.63M$5.01M$3.63M
    Operating Expenses$21.29M$12.62M$12.32M$10.64M$9.22M$13.40M$10.33M$5.85M$5.79M$8.56M$5.81M$5.62M
    R&D$5.27M$993,000$1.88M$1.78M$1.11M$3.71M$1.16M$-871,000$505,000$2.97M$651,000$1.05M
    SG&A$16.02M$11.63M$10.45M$8.86M$8.11M$9.69M$9.17M$6.72M$5.29M$5.59M$5.16M$4.58M
    Operating Income$23.01M$12.79M$2.41M$2.46M$-1,363,000$-1,475,000$-470,000$629,000$509,000$-2,935,000$-800,000$-1,993,000
    Interest Income$-656,000$-1,076,000$-840,000$0$-592,000$-1,044,000$-1,028,000$0$-8,000$-52,000$-11,000$0
    Interest Expense$656,000$1.08M$840,000$1.05M$592,000$1.04M$1.03M$1.14M$8,000$52,000$11,000$16,000
    Income Before Tax$22.36M$11.72M$1.57M$1.41M$-1,955,000$-2,519,000$-1,498,000$-511,000$501,000$-2,987,000$-811,000$-2,009,000
    Income Tax Expense$-12,892,000$140,000$20,000$-69,000$-28,000$66,000$74,000$87,000$-126,000$54,000$0$247,000
    Net Income$35.25M$11.58M$1.55M$1.48M$-1,927,000$-2,585,000$-1,572,000$-598,000$627,000$-3,041,000$-811,000$-2,256,000
    EBITDA$24.67M$14.34M$3.66M$3.66M$-175,000$-422,000$837,000$2.02M$809,000$-2,633,000$-541,000$-1,938,000
    EBIT$23.01M$12.79M$2.41M$2.46M$-1,363,000$-1,475,000$-470,000$629,000$509,000$-2,935,000$-800,000$-2,290,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ETON

    News

    Eton stock jumps on Q3 beat and guidance hike (ETON:NASDAQ)

    Eton Pharmaceuticals' stock surged over 20% in premarket trading after reporting strong Q3 2026 financial results that exceeded expectations. The rare disease drugmaker also raised its full-year guidance...

    Seeking Alpha•11/6/26•Bullish

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    This article details 12 health care stocks that experienced significant movement in Friday's pre-market session. Six companies, including Milestone Scientific and Eton Pharmaceuticals, saw their stock prices rise...

    Benzinga•11/6/26•Neutral

    Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion

    Eton Pharmaceuticals (ETON) reported strong third-quarter 2026 earnings, surpassing revenue and EPS estimates, driven by accelerating rare disease product sales and pipeline progress. The company raised its full-year...

    TradingView•11/6/26•Neutral

    Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability

    Eton Pharmaceuticals announced preliminary results from a pilot study for ET-700, an investigational extended-release zinc acetate formulation for Wilson disease...

    The Manila Times•11/5/26•Somewhat-Bullish

    ETON: Record revenue, 49% adjusted EBITDA margin and an expanding late-stage pipeline

    Eton Pharmaceuticals (ETON) reported a significant increase in Q3 2026 revenue, rising 158% year-over-year to $57.9M...

    TradingView•11/5/26•Bullish

    ETON Valuation and Fair Value

    P/E
    32.4x
    Forward P/E
    21.9x
    EV/EBITDA
    34.2x
    P/FCF
    42.4x
    P/B
    18.6x
    See GNG's fair value

    ETON Profitability: Margins, ROIC and FCF

    Gross margin
    69.2%
    Operating margin
    35.8%
    Net margin
    12.0%
    ROIC
    37.0%
    ROE
    36.0%
    FCF margin
    27.1%
    FCF yield
    2.4%

    ETON Competitors

    CompanyTicker
    Structure Therapeutics Inc. American Depositary SharesGPCR
    Mineralys Therapeutics, Inc. Common StockMLYS
    Kalvista Pharmaceuticals IncKALV
    STAAR Surgical CompanySTAA
    Cronos Group IncCRON
    Taysha Gene Therapies IncTSHA
    Innoviva IncINVA
    Opko Health IncOPK

    Sector: Healthcare

    ETON Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ETON Bull Case vs Bear Case

    Bull case

    • ETON earns a 37.0% return on invested capital.
    • ETON converts 27.1% of revenue into free cash flow.
    • ETON grew quarterly revenue 98.6% year over year.

    Bear case

    • ETON beat EPS estimates in 37.5% of its last 8 reported quarters.

    ETON Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -158.2%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.70

    ETON Earnings Date

    ETON reports Mar 17, 2027, after the close. The date is estimated.

    ETON Earnings Call

    The latest ETON earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    ETON ETF Holders

    GNG tracks 8 ETFs that hold ETON. The largest weights:

    1. State Street SPDR S&P Pharmaceuticals ETF (XPH), 1.77% of the fund
    2. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.61% of the fund
    3. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    4. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    5. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for ETON

    See insider activity

    Frequently Asked Questions About ETON

    When does ETON report earnings?

    Eton Pharmaceuticals Inc (ETON) is expected to report earnings on Mar 17, 2027.

    Does ETON pay dividends?

    Eton Pharmaceuticals Inc (ETON) does not currently pay a regular dividend.

    What is ETON's P/E ratio?

    Eton Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 32.45.

    What is ETON's market cap?

    Eton Pharmaceuticals Inc (ETON) has a market capitalization of $1.35B with a current stock price of $56.46.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In